OncoMatch/Clinical Trials/NCT05903807

[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer

Is NCT05903807 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 68Ga-FAPi-46 for ovarian cancer.

Phase 2RecruitingAalborg University HospitalNCT05903807Data as of May 2026

Treatment: 68Ga-FAPi-46 — Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using histopathology as reference standard, and the diagnostic accuracy will be determined. FAP-immunohistochemistry will be conducted in surgical specimens. FAPI PET/CT's impact on patient management and the prognostic value of FAPI PET/CT will be evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify